AU2020386971A1 - Methods for providing continuous therapy against PNAG comprising microbes - Google Patents

Methods for providing continuous therapy against PNAG comprising microbes Download PDF

Info

Publication number
AU2020386971A1
AU2020386971A1 AU2020386971A AU2020386971A AU2020386971A1 AU 2020386971 A1 AU2020386971 A1 AU 2020386971A1 AU 2020386971 A AU2020386971 A AU 2020386971A AU 2020386971 A AU2020386971 A AU 2020386971A AU 2020386971 A1 AU2020386971 A1 AU 2020386971A1
Authority
AU
Australia
Prior art keywords
vaccine
charged
formula
reactor
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020386971A
Other languages
English (en)
Inventor
Gerald F. SWISS
Michael Wyand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alopexx Inc
Original Assignee
Alopexx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alopexx Inc filed Critical Alopexx Inc
Publication of AU2020386971A1 publication Critical patent/AU2020386971A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020386971A 2019-11-22 2020-11-20 Methods for providing continuous therapy against PNAG comprising microbes Pending AU2020386971A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962939331P 2019-11-22 2019-11-22
US62/939,331 2019-11-22
US202062994130P 2020-03-24 2020-03-24
US62/994,130 2020-03-24
PCT/US2020/061594 WO2021102320A1 (en) 2019-11-22 2020-11-20 Methods for providing continuous therapy against pnag comprising microbes

Publications (1)

Publication Number Publication Date
AU2020386971A1 true AU2020386971A1 (en) 2022-06-09

Family

ID=75980043

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020386971A Pending AU2020386971A1 (en) 2019-11-22 2020-11-20 Methods for providing continuous therapy against PNAG comprising microbes

Country Status (11)

Country Link
US (1) US20230053458A1 (enExample)
EP (1) EP4061411A4 (enExample)
JP (2) JP2023502276A (enExample)
KR (1) KR20220107001A (enExample)
CN (1) CN114845731A (enExample)
AU (1) AU2020386971A1 (enExample)
BR (1) BR112022009924A2 (enExample)
CA (1) CA3162238A1 (enExample)
IL (1) IL293091A (enExample)
WO (1) WO2021102320A1 (enExample)
ZA (1) ZA202205546B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3152520A1 (en) * 2019-08-27 2021-03-04 OneBioPharma, Inc. Antimicrobial vaccine compositions
US11173199B2 (en) * 2019-11-13 2021-11-16 Alopexx Inc. Low contaminant compositions
WO2023173020A1 (en) * 2022-03-11 2023-09-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody materials and methods targeting microbial polysaccharides

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2415358T3 (es) * 2004-04-21 2013-07-25 The Brigham And Women's Hospital, Inc. Péptidos de fijación a la poli-N-acetil glucosamina (PNAG/DPNAG) y procedimientos para el uso de los mismos
CN102159540B (zh) * 2008-07-21 2015-08-12 布赖汉姆妇女医院 与合成的β-1,6葡糖胺寡糖相关的方法和组合物
US20130116423A1 (en) * 2010-04-23 2013-05-09 A. Stewart Campbell Synthetic Oligosaccharides for Staphylococcus Vaccine
WO2012145626A1 (en) * 2011-04-22 2012-10-26 Ancora Pharmaceuticals Inc. Synthetic oligosaccharides for staphylococcus vaccine
US20150086601A1 (en) * 2012-05-07 2015-03-26 Sanofi Methods for preventing biofilm formation
MX2014013637A (es) * 2012-05-07 2015-02-05 Sanofi Sa Metodos para prevencion de la formacion de biopelicula.
RU2019101166A (ru) * 2012-05-30 2020-03-02 Дзе Брихэм Энд Уимен`З Хоспитал, Инк. Композиции полисахаридов и способы применения
US10828360B1 (en) * 2020-02-04 2020-11-10 OneBioPharma, Inc. Methods for inhibiting biofilm formation

Also Published As

Publication number Publication date
JP2026016535A (ja) 2026-02-03
BR112022009924A2 (pt) 2022-08-09
WO2021102320A1 (en) 2021-05-27
CN114845731A (zh) 2022-08-02
JP2023502276A (ja) 2023-01-23
ZA202205546B (en) 2023-05-31
US20230053458A1 (en) 2023-02-23
CA3162238A1 (en) 2021-05-27
KR20220107001A (ko) 2022-08-01
EP4061411A1 (en) 2022-09-28
IL293091A (en) 2022-07-01
EP4061411A4 (en) 2023-11-29

Similar Documents

Publication Publication Date Title
JP2026016535A (ja) Ｐｎａｇを含む微生物に対する持続的治療を提供するための方法
JP7277459B2 (ja) クレブシエラ ニューモニエ（Ｋｌｅｂｓｉｅｌｌａ ｐｎｅｕｍｏｎｉａｅ）に対するワクチン
US20140170151A1 (en) Synthetic Oligosaccharides for Staphylococcus Vaccine
US20210244808A1 (en) Methods for inhibiting biofilm formation
JP2026021461A (ja) 低汚染抗菌ワクチン
JP2025148346A (ja) 抗菌性ワクチン組成物
JP2018537428A (ja) カンピロバクター・ジェジュニに対する合成抗原コンストラクト
KR102803369B1 (ko) 클로스트리듐 디피실에 대한 안정성 백신
US12351596B2 (en) Tetrasaccharides for the diagnosis, prevention, and treatment of melioidosis and glanders
HK40077830A (en) Methods for providing continuous therapy against pnag comprising microbes
HK40078447A (en) Low contaminant antimicrobial vaccines
HK40076154A (en) Antimicrobial vaccine compositions
CA2126341A1 (en) Lipid-a analogs: new monosaccharide and dissaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities